We are focused on finding and developing products and services that meet the needs of endocannabinology; dietary supplements, laboratory diagnostic tools, IT solutions, medicines and medical devices. Although we are starting with cannabis derived products, further development will focus on non-cannabis related products.
In 2020 we are planning to introduce the endocannabinoid PEA (palmytoylethanolamide): “PEA reduces SCI-associated inflammation and tissue damage and suggests a regulatory role for endogenous PPAR-alpha signaling in the inflammatory response associated with spinal cord trauma.”
The goal of our development is to achieve a situation where we will be able to tailor each client’s dietary supplements according to their individual needs. #mixability